Deletions of the 3'BCR and 5'ABL regions in patients with Philadelphia-positive chronic myeloid leukemia: a one-step process occurring in about 10% of the cases without any evidence of genetic instability in the target cells.
Deletions of the 5'ABL region adjacent to the t(9;22)(q34;q11) have recently been reported in 8-32.7% of patients with chronic myeloid leukemia (CML). The deletions were visualized with fluorescence in situ hybridization using, in the majority of the cases, the Vysis LSI BCR/ABL ES (extra signal) probe. In our series, 10 of 99 CML patients (10.1%) were characterized by a 5'ABL deletion. We show that 3'BCR losses are observed in nearly all the cases with 5'ABL deletions. Moreover, the different genetic events (Philadelphia chromosome formation; 5'ABL and 3'BCR deletions) occur simultaneously in a one-step process without any evidence for genetic instability in the target bone marrow cells.
Fournier
Mickaël
M
Center for Human Genetics, University of Liège, CHU, Tour de Pathologie, B23, Sart Tilman, 4000 Liège, Belgium.
Lacrosse
Stéphanie
S
Jamar
Mauricette
M
Bours
Vincent
V
Herens
Christian
C
D005260:Female; D016044:Fusion Proteins, bcr-abl / Q000235:genetics*; D042822:Genomic Instability / Q000235:genetics*; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D017384:Sequence Deletion / Q000235:genetics*
D016044:Fusion Proteins, bcr-abl